1ZUA

Crystal Structure Of AKR1B10 Complexed With NADP+ And Tolrestat

1ZUA の概要

• エントリーDOI: 10.2210/pdb1zua/pdb
• 関連するPDBエントリー: 1ADS 1AH3 1C9W
• 分子名称: Aldo-keto reductase family 1 member B10, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, TOLRESTAT, ... (4 entities in total)
• 機能のキーワード: alpha-beta barrel, aldo-keto reductase, oxidoreductase
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Cytoplasm (Probable): O60218
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 37310.44

構造登録者

Gallego, O.,Ruiz, F.X.,Ardevol, A.,Dominguez, M.,Alvarez, R.,de Lera, A.R.,Rovira, C.,Farres, J.,Fita, I.,Pares, X. (登録日: 2005-05-30, 公開日: 2006-11-07, 最終更新日: 2023-10-25)

主引用文献

Gallego, O.,Ruiz, F.X.,Ardevol, A.,Dominguez, M.,Alvarez, R.,de Lera, A.R.,Rovira, C.,Farres, J.,Fita, I.,Pares, X.
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Proc.Natl.Acad.Sci.USA, 104:20764-20769, 2007

PubMed Abstract: AKR1B10 is a human aldo-keto reductase (AKR) found to be elevated in several cancer types and in precancerous lesions. In vitro, AKR1B10 exhibits a much higher retinaldehyde reductase activity than any other human AKR, including AKR1B1 (aldose reductase). We here demonstrate that AKR1B10 also acts as a retinaldehyde reductase in vivo. This activity may be relevant in controlling the first step of retinoic acid synthesis. Up-regulation of AKR1B10, resulting in retinoic acid depletion, may lead to cellular proliferation. Both in vitro and in vivo activities of AKR1B10 were inhibited by tolrestat, an AKR1B1 inhibitor developed for diabetes treatment. The crystal structure of the ternary complex AKR1B10-NADP(+)-tolrestat was determined at 1.25-A resolution. Molecular dynamics models of AKR1B10 and AKR1B1 with retinaldehyde isomers and site-directed mutagenesis show that subtle differences at the entrance of the retinoid-binding site, especially at position 125, are determinant for the all-trans-retinaldehyde specificity of AKR1B10. Substitutions in the retinaldehyde cyclohexene ring also influence the specificity. These structural features should facilitate the design of specific inhibitors, with potential use in cancer and diabetes treatments.

PubMed: 18087047
DOI: 10.1073/pnas.0705659105

実験手法

X-RAY DIFFRACTION (1.25 Å)